EE619 A Cost-Utility Analysis of Low-Dose vs Standard-Dose Intravenous Alteplase in the Management of Acute Non-Lacunar Ischaemic Strokes: A Perspective From the NHS

Studies exploring the efficacy and safety of low-dose (0.6 mg/kg) vs standard-dose (0.9mg/kg) intravenous alteplase in treating acute non-lacunar ischaemic strokes (aNLIS) have shown no significant difference in treatment effects, however, the risk of symptomatic intracerebral haemorrhage (ICH) is reduced with low dose alteplase. The aim of this study was to perform a cost-utility analysis (CUA) of low-dose and standard-dose intravenous alteplase in treating aNLIS.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research